BiotechTube

RG6496 + Placebo

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Nov 19, 2025 → Mar 5, 2029

NCT ID
NCT07246941

About RG6496 + Placebo

RG6496 + Placebo is a phase 1 stage product being developed by Roche for Huntington's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07246941. Target conditions include Huntington's Disease.

What happened to similar drugs?

1 of 2 similar drugs in Huntington's Disease were approved

Approved (1) Terminated (1) Active (0)
✅TetrabenazineLundbeckApproved
❌SAGE-718Supernus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07246941Phase 1Recruiting

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
27
RO7234292 (RG6042)RochePhase 2
35
PF-02545920 + PF-02545920PfizerPhase 2
35
20 mg BID of PF-02545920PfizerPhase 2
27
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
35
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
33
TetrabenazineLundbeckApproved
36
BN82451B + PlaceboIpsenPhase 2
24
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
29
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
18
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
18
SAGE-718Supernus PharmaceuticalsPhase 3
26
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
29
OMS643762 + PlaceboOmeros CorporationPhase 2
21
VX15/2503 + PlaceboVaccinexPhase 2
25